Utpal Mohan

Dr. Utpal Mohan


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PPPragya Prasanna
Pragya Prasanna
PKPrakash Kumar
Prakash Kumar
SKSaurabh Kumar
Saurabh Kumar
VRVinod Kumar Rajana
Vinod Kumar Rajana
VKVishnu Kant
Vishnu Kant
DMDebabrata Mandal
Debabrata Mandal
The study of tropical diseases like leishmaniasis, a parasitic disease, has not received much attention even though it is the second-largest infectious disease after malaria. As per the WHO report, a total of 0.7-1.0 million new leishmaniasis cases, which are spread by 23 Leishmania species in more than 98 countries, are estimated with an alarming 26,000-65,000 death toll every year. Lack of potential vaccines along with the cost and toxicity of amphotericin B (AmB), the most common drug for the treatment of leishmaniasis, has raised the interest significantly for new formulations and drug delivery systems including nanoparticle-based delivery as anti-leishmanial agents. The size, shape, and high surface area to volume ratio of different NPs make them ideal for many biological applications. The delivery of drugs through liposome, polymeric, and solid-lipid NPs provides the advantage of high biocomatibilty of the carrier with reduced toxicity. Importantly, NP-based delivery has shown improved efficacy due to targeted delivery of the payload and synergistic action of NP and payload on the target. This review analyses the advantage of NP-based delivery over standard chemotherapy and natural product-based delivery system. The role of different physicochemical properties of a nanoscale delivery system is discussed. Further, different ways of nanoformulation delivery ranging from liposome, niosomes, polymeric, metallic, solid-lipid NPs were updated along with the possible mechanisms of action against the parasite. The status of current nano-vaccines and the future potential of NP-based vaccine are elaborated here.

1 September 2010 in Bioresource Technology
Verified
Journal Article
Closed access
SKSandeep Kumar
Sandeep Kumar
UMUtpal Mohan
Utpal Mohan
AKAshwini L. Kamble
Ashwini L. Kamble
SPSandip Pawar
Sandip Pawar
UBUttam Chand Banerjee
Uttam Chand Banerjee

7 September 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
PKPoonam Kumari
Poonam Kumari
SBSujoy Bowmik
Sujoy Bowmik
SPSudipto Kumar Paul
Sudipto Kumar Paul
BBBidisha Biswas
Bidisha Biswas
SBSanjay K. Banerjee
Sanjay K. Banerjee
UMUtpal Mohan
Utpal Mohan

8 April 2024 in Indian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
RBRashmita Biswas
Rashmita Biswas
BJBhawana Jangra
Bhawana Jangra
GAGanapathy Ashok
Ganapathy Ashok
VRVelayutham Ravichandiran
Velayutham Ravichandiran
UMUtpal Mohan
Utpal Mohan

2 January 2023 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
SYSai Sumanjali Yarra
Sai Sumanjali Yarra
GAGanapathy Ashok
Ganapathy Ashok
UMUtpal Mohan
Utpal Mohan

2 August 2023 in ACS Omega
Verified
Journal Article
Open access
Shakilur RahmanShakilur Rahman
Shakilur Rahman
SNSubham Nath
Subham Nath
UMUtpal Mohan
Utpal Mohan
ADAmit Kumar Das
Amit Kumar Das
Staphylococcus aureus-mediated infection is a serious threat in this antimicrobial-resistant world. S. aureus has become a "superbug" by challenging conventional as well as modern treatment strategies. Nowadays, drug repurposing has become a new trend for the discovery of new drug molecules. This study focuses on evaluating FDA-approved drugs that can be repurposed against S. aureus infection. Steered molecular dynamics (SMD) has been performed for Lumacaftor and Olaparib against staphylococcal FemX to understand their binding to the active site. A time-dependent external force or rupture force has been applied to the ligands to calculate the force required to dislocate the ligand from the binding pocket. SMD analysis indicates that Lumacaftor has a high affinity for the substrate binding pocket in comparison to Olaparib. Umbrella sampling exhibits that Lumacaftor possesses a higher free energy barrier to displace it from the ligand-binding site. The bactericidal activity of Lumacaftor and Olaparib has been tested, and it shows that Lumacaftor has moderate activity along with biofilm inhibition potential (MIC value with conc. 128 μg/mL). Pharmacokinetic and toxicology evaluations indicate that Lumacaftor has higher pharmacokinetic potential with lower toxicity. This is the first experimental report where staphylococcal FemX has been targeted for the discovery of new drugs. It is suggested that Lumacaftor may be a potential lead molecule against S. aureus.